The Optimal Medical Therapy for Glycemic Control in COVID-19

Diabetes is highly linked to the severity of coronavirus disease 2019 (COVID-19). My recent meta-analysis also suggested a higher prevalence diabetes in severe COVID-19 as compared with non-severe COVID-19. Recent observational studies have shown that hyperglycemia was significantly associated both diabetic and non-diabetic patients. To prevent worse outcome COVID-19, more tight glucose control required. I studied association between putative beneficial harmful effects, clinical outcomes oral hypoglycemic drugs insulin use glycemic among patients, by searching literatures. Although there were some negative studies, reported treatment using metformin reduction mortality due One study showed sitagliptin, one dipeptidyl peptidase-4 (DPP4) inhibitors, during hospitalization mortality, improvement patients on standard care. There no effects glucagon-like peptide-1 receptor agonists, pioglitazone sulfonylurea outcomes. Regarding sodium-glucose cotransporter 2 (SGLT2) case euglycemic ketoacidosis (DKA) DKA difficult distinguish from reported. who need hospital care may deteriorate rapidly, an early appropriate initiation therapy hyperglycemic be encouraged. J Endocrinol Metab. 2021;11(1):1-7 doi: https://doi.org/10.14740/jem718